Skip to content
GLP-1 Desk
Menu

Head-to-head dispatch

Ro vs Hims & Hers

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Dispatch #16EditorialDesk pick
Ro

A heavyweight platform with brand-name access — but opaque compounded pricing clouds its dispatch.

vs
Dispatch #24Editorial
Hims & Hers

Mass-market app-first program with nationwide polish — tirzepatide pricing disclosure lags the board.

Ro takes this head-to-head with the higher Desk Score, 81/100 (B−) against 76/100 (C) for Hims & Hers. Hims & Hers still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Ro

81/100

B−

Overall

Hims & Hers

76/100

C

Price transparency

62
74

State access

84
94

Molecule range

88
74

Onboarding speed

78
80

Support responsiveness

82
74

Licensing & trust

84
76

The spec sheet

FieldRoHims & Hers
SemaglutideNot disclosed$199/mo
TirzepatideNot disclosedNot disclosed
CoverageMulti-stateAll 50 states
Brand-nameYesCompounded only
Oral optionYesInjectable only
Best forPatients who want brand-name capability and insurance navigation support.People who want a familiar consumer-brand app experience and don't need tirzepatide.
Desk Score81/100B−76/100C

The verdict

Desk pick — Ro

Ro takes this head-to-head with the higher Desk Score, 81/100 (B−) against 76/100 (C) for Hims & Hers. Hims & Hers still holds its ground where its strengths line up with yours.

Choose Ro if…

Patients who want brand-name capability and insurance navigation support.

Not disclosed sema · Not disclosed tirz · Multi-state

Choose Hims & Hers if…

People who want a familiar consumer-brand app experience and don't need tirzepatide.

$199/mo sema · Not disclosed tirz · All 50 states

Neither provider here is a commercial partner. Read full breakdowns: Ro · Hims & Hers.

Also on the board

CoreAge Rx tops every dispatch at 94/100

Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.

More head-to-heads

Or see the full comparison hub and the complete board.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.